SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Recruiting now

Conditions studied: HIV Infections

In brief

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Key facts

Study ID

NCT00187512

Run by

University of California, San Francisco

People needed

2500

Starts

2000-03-01

Expected to finish

2033-12-01

Last updated by the study team

2025-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:
• Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
• Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.
• Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.
• Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.

You may not qualify if…

• Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
• Active treatment for cancer
• Active treatment for hepatitis C requiring interferon based therapy
• Immunosuppressive therapy taken within the last 4 months

Where it is running

• San Francisco General Hospital — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.